Olszanski, A. J., Bauman, J. R., Kinder, H., Mehren, M. V., LEE, T., Borghaei, H., Vijayvergia, N., Hall, M. J., Khan, K., Hayat, U., Altieri, D. C. (2026). A phase 1, first-in-human, open-label, dose-escalation and -expansion study of gamitrinib, a first-in-class, mitochondria-directed inhibitor of the molecular chaperone heat shock protein-90 (Hsp90) in patients with advanced cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps3180